PMID- 37746269 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231020 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 13 DP - 2023 TI - Transcatheter arterial chemoembolization combined with apatinib and camrelizumab for unresectable advanced gastric or gastroesophageal junction cancer: a single-arm, single-center, retrospective study. PG - 1143578 LID - 10.3389/fonc.2023.1143578 [doi] LID - 1143578 AB - PURPOSE: This study aims to investigate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with Apatinib and Camrelizumab for treating unresectable advanced gastric or gastroesophageal junction (G/GEJ) cancer. MATERIAL AND METHODS: In this study, data of patients with unresectable advanced G/GEJ cancer who received TACE combined with Apatinib and Camrelizumab from August 2018 to December 2021 was evaluated. After TACE, patients were given intravenous Camrelizumab 200mg every three weeks and oral apatinib 250mg/day for treatment. The primary endpoint was overall survival (OS), and the secondary endpoints were objective response rate (ORR), disease control rate (DCR), and adverse events (AEs). RESULTS: A total of 49 patients were enrolled in this study. The median follow-up time was 14.0 months, and the median OS was 20.0 months (95% CI = 13.6-26.4). Two patients (4.08%) achieved complete remission, 28 patients (57.14%) achieved partial remission, 18 patients (36.73%) had stable disease, and 1 patient (2.04%) had disease progression. The ORR was 61.22%, and the DCR was 97.96%. Multivariate Cox regression analysis indicated that age (HR 4.74, 95% CI = 1.674-13.440, P=0.003) and multiple distant metastases (HR 20.916, 95% CI = 4.094-106.808, P = 0.001) were independent risk factors for OS. Most AEs were classified as grade 1-2, the most common being RCCEP (69.39%). There were 5 cases of grade 3-4 adverse events (10.20%). No patients discontinued or reduced the treatment dose due to AEs, and all patients received symptomatic treatment. CONCLUSION: TACE combined with Apatinib and Camrelizumab is a safe and effective therapeutic option for patients with unresectable advanced G/GEJ cancer, which can significantly improve the median OS and ORR of patients. And the adverse events (AEs) are tolerable and manageable. CI - Copyright (c) 2023 Wu, Li, Li, Zhou, Ge, Li, Han, Chen and Ren. FAU - Wu, Kunpeng AU - Wu K AD - Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. AD - Interventional Institute of Zhengzhou University, Zhengzhou, Henan, China. AD - Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, Henan, China. FAU - Li, Yahua AU - Li Y AD - Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. AD - Interventional Institute of Zhengzhou University, Zhengzhou, Henan, China. AD - Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, Henan, China. FAU - Li, Zongming AU - Li Z AD - Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. AD - Interventional Institute of Zhengzhou University, Zhengzhou, Henan, China. AD - Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, Henan, China. FAU - Zhou, Zihe AU - Zhou Z AD - Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. AD - Interventional Institute of Zhengzhou University, Zhengzhou, Henan, China. AD - Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, Henan, China. FAU - Ge, Xiaoyong AU - Ge X AD - Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. AD - Interventional Institute of Zhengzhou University, Zhengzhou, Henan, China. AD - Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, Henan, China. FAU - Li, Yifan AU - Li Y AD - Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. AD - Interventional Institute of Zhengzhou University, Zhengzhou, Henan, China. AD - Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, Henan, China. FAU - Han, Xinwei AU - Han X AD - Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. AD - Interventional Institute of Zhengzhou University, Zhengzhou, Henan, China. AD - Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, Henan, China. FAU - Chen, Peng AU - Chen P AD - Department of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. FAU - Ren, Kewei AU - Ren K AD - Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. AD - Interventional Institute of Zhengzhou University, Zhengzhou, Henan, China. AD - Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, Henan, China. LA - eng PT - Journal Article DEP - 20230906 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC10512224 OTO - NOTNLM OT - TACE OT - comprehensive therapy OT - gastric or gastroesophageal junction cancer OT - immunotherapy OT - targeted therapy COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/09/25 06:42 MHDA- 2023/09/25 06:43 PMCR- 2023/01/01 CRDT- 2023/09/25 05:14 PHST- 2023/01/13 00:00 [received] PHST- 2023/08/21 00:00 [accepted] PHST- 2023/09/25 06:43 [medline] PHST- 2023/09/25 06:42 [pubmed] PHST- 2023/09/25 05:14 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2023.1143578 [doi] PST - epublish SO - Front Oncol. 2023 Sep 6;13:1143578. doi: 10.3389/fonc.2023.1143578. eCollection 2023.